Associations - KRAS G12V

BIOMARKER:

KRAS G12V

Entrez ID:

3845

Related biomarkers:

‹

›

KRAS G12V KRAS G12V	Colorectal Cancer CRC	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B
KRAS G12V KRAS G12V	Colorectal Cancer CRC	cetuximab Resistant: B - Late Trials cetuximab Resistant : B
KRAS G12V KRAS G12V	Non Small Cell Lung Cancer NSCLC	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
KRAS G12V KRAS G12V	Spindle Cell Sarcoma Spindle Cell Sarcoma	BAL3833 Sensitive: C3 – Early Trials BAL3833 Sensitive : C3
KRAS G12V KRAS G12V	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
KRAS G12V KRAS G12V	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3
KRAS G12V KRAS G12V	Hepatocellular Cancer HCC	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
KRAS G12V KRAS G12V	Non Small Cell Lung Cancer NSCLC	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3
KRAS G12V KRAS G12V	Non Small Cell Lung Cancer NSCLC	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3
KRAS G12V KRAS G12V	Non Small Cell Lung Cancer NSCLC	VS-6766 Sensitive: C3 – Early Trials VS-6766 Sensitive : C3
KRAS G12V KRAS G12V	Colorectal Cancer CRC	RGX-202 Sensitive: C3 – Early Trials RGX-202 Sensitive : C3
KRAS G12V KRAS G12V	Ovarian Cancer Ovarian Cancer	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3
KRAS G12V KRAS G12V	Colorectal Cancer CRC	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3
KRAS G12V KRAS G12V	Lung Adenocarcinoma LUAD	osimertinib Resistant: C4 – Case Studies osimertinib Resistant : C4
KRAS G12V KRAS G12V	Colorectal Cancer CRC	AZ 628 Resistant: D – Preclinical AZ 628 Resistant : D
KRAS G12V KRAS G12V	Colon Cancer Colon Cancer	CDK9 inhibitor Sensitive: D – Preclinical CDK9 inhibitor Sensitive : D
KRAS G12V KRAS G12V	Colorectal Cancer CRC	selumetinib + AZ 628 Sensitive: D – Preclinical selumetinib + AZ 628 Sensitive : D
KRAS G12V KRAS G12V	Colorectal Cancer CRC	selumetinib Resistant: D – Preclinical selumetinib Resistant : D
KRAS G12V KRAS G12V	Non Small Cell Lung Cancer NSCLC	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D
KRAS G12V KRAS G12V	Non Small Cell Lung Cancer NSCLC	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
KRAS G12V KRAS G12V	Colorectal Cancer CRC	sunitinib Resistant: D – Preclinical sunitinib Resistant : D
KRAS G12V KRAS G12V	Ovarian Cancer Ovarian Cancer	trametinib Sensitive: D – Preclinical trametinib Sensitive : D
KRAS G12V KRAS G12V	Colorectal Cancer CRC	P1446A-05 Sensitive: D – Preclinical P1446A-05 Sensitive : D

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES